LEGAL NOTICES AND DISCLAIMERS

PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEB SITE. BY ACCESSING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THIS SITE.

DOR BioPharma is working hard to ensure that the information provided on this site is accurate and up-to-date but due to the risk that the information may be comprised by software or procedural errors, does not guarantee the accuracy or completeness of the information provided on this site. DOR BioPharma reserves the right to make changes to the content of this site from time to time without notice or obligation.

Permission to Browse Site and Limited Permission to Make Copies:

You may browse this site for information and may print copies of its contents for your own use. Written permission is required, however, if you want to incorporate the contents into you own site or written materials, create "derivative works" or revise the site contents. In addition, you may not "mirror" the contents of this site without DOR BioPharma's permission. To seek permission, please email info@dorbiopharma.com

Remember:
Although it may be easy to copy in cyberspace, this does not mean it is legal to do so.

Photo Credits:
PhotoDisc, The Image Works, meister.NET and DOR BioPharma

Trademarks:
Oraprine™, OrBec™, LPM™, LPE™, PLP™ and MicroVax™ are trademarks of DOR BioPharma Corporation. Registrations exist in the United States and various countries throughout the world. Biothrax™ is a trademark of the Bioport Corporation. Imuran® is a registered trademark of Glaxo Wellcome. Taxol® is a registered trademark of Bristol Myers Squibb. Lupron® is a registered trademark of TAP Pharmaceuticals, Inc. For more complete information regarding the status of a particular trademark in a particular country, please contact DOR BioPharma.

Copyrights:
Copyright in the pages and in the screens displaying the pages, and in the information and material therein and in their arrangement, is owned by the DOR BioPharma Corporation unless otherwise indicated. Some contents of this site may be registered with the Federal Copyright Office. Please familiarize yourself with US and International Copyright laws before using any material.

Links to Third Party Sites:
Please understand that when you access another web site through this one, DOR BioPharma can accept no responsibility for your experience with the site. in addition, a link to a non-DOR BioPharma site does not mean that DOR BioPharma endorses or recommends that site or its contents.

Stock Information:
The information provided under "Get Our Quote, Amex" in the Investor Relations section of this site is provided through a hypertext link to a third party Web site. (See above for important information about links to third party Web sites.) Under no circumstances will DOR BioPharma be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the risks of the stock market.

Communications with DOR BioPharma:
Any communications or material transmitted to DOR BioPharma will be treated as non-confidential and non-proprietary. DOR BioPharma shall be free to reproduce, use, disclose and distribute these communications to third parties without restriction. DOR BioPharma shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.

No Warranties; Limitations of Liability:
DOR BioPharma assumes no responsibility for errors or omissions on this web site. ACCESS TO THIS SITE IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. DOR BioPharma shall not be liable for any special, indirect, incidental, or consequential damages, including without limitation, lost revenues or lost profits, which may result for the use of this site.

Privacy:
Anyone using this server acknowledges that DOR BioPharma may monitor the server contents as needed to comply with the law, to protect DOR BioPharma and visitors to this site or server and to ensure that the server is being operated properly.

Located in Lake Forest, Illinois, DOR BioPharma, Inc. is a pharmaceutical company specializing in the oral and mucosal delivery of drugs and vaccines. Through our newly-formed Biodefense Division, we are developing vaccines for a series of biological agents that currently pose a significant bioterrorism or biowarfare threat. Our vaccines are based on the MicroVax™ technology, a proprietary encapsulation system that protects sensitive vaccine materials and permits their efficient delivery to the body’s immune system.

Additionally, our Biotherapeutics Division is developing oral and mucosal drugs which are traditionally delivered in non-oral formats. We anticipate our oral products will enhance patient quality of life, patient compliance to therapy and potentially reduce healthcare costs. The Company’s lead product, orBec® (oral beclomethasone dipropionate), is currently in a pivotal phase III clinical trial for the treatment of intestinal graft-vs.-host disease and the Company is currently testing orBec®’s usefulness in treating a large percentage of persons diagnosed with irritable bowel syndrome (IBS), a disease that affects approximately 35 million persons in the U.S. alone.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company’s periodic reports on Form 10-KSB and 10-QSB, and any prospectus describing the Company’s securities.